Colman, H., Lombardi, G., Wong, E. T., Walbert, T., Eoli, M., Lassman, A. B., Peereboom, D. M., Kizilbash, S. H., Kamiya-Matsuoka, C., Pitz, M. W., Strowd, R. E., Desjardins, A., Kumthekar, P., Mason, W., Pellerino, A., Soffietti, R., Butowski, N., Forsyth, P. A., Hamza, M. A., Hau, P., Lallana, E., Nabors, B., Piccioni, D., Uhlmann, E. J., Welsh, L. C., Wen, P. Y., Dietrich, J., Wang, C., Levin, V. A. (2026). STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-01204